The central objective of increasing the security and military costs imposed on Iran is not necessarily to launch an all-out war, but rather to compel the Iranian leadership to accept a new deal.
Donald Trump’s proposed 200% tariff on generic drug imports is less a blow to India’s pharmaceutical industry than a costly gamble that could leave American patients paying the highest price.